Softwave Shockwave: What It Does and What It Doesn't

Shockwave therapy is one of those modalities that's been around for decades but is mostly known for the wrong reasons. It was originally developed in the 1980s to break up kidney stones (lithotripsy), and the same physical principle, repurposed at lower energies, turns out to be useful for orthopedic soft tissue.

At Apex we use Softwave specifically, which is an unfocused electrohydraulic shockwave system. The distinction matters because the orthopedic device market includes a lot of products marketed as "shockwave" that are actually radial pressure-wave devices. They feel similar to a patient. They're not biologically equivalent.

This guide covers the physics, the mechanism, the published evidence by indication, what a session is actually like, when we use it standalone, when we use it as a regen adjunct, and the common red flags in how it gets marketed.

A short history

The physical principle behind shockwave therapy goes back to the early 1980s, when researchers at Dornier in Germany developed extracorporeal shockwave lithotripsy (ESWL) to break up kidney stones non-invasively. The same focused acoustic energy that fragments calcium oxalate stones turned out, at much lower energy levels, to do something interesting to soft tissue: it stimulated repair.

By the mid-1990s, ESWT (extracorporeal shockwave therapy) was being used clinically in Europe for orthopedic soft tissue conditions, particularly tendinopathies and calcific tendinitis. The FDA cleared the first orthopedic ESWT devices in the United States in 2000 for plantar fasciitis, with subsequent clearances for lateral epicondylitis and other indications.

Through the 2000s and 2010s, the device landscape diversified. Focused shockwave (the original ESWL-derived technology) was joined by radial pressure-wave devices, which use a compressed-air-driven projectile to deliver lower-amplitude pressure pulses across a wider area near the surface. The two modalities began to be marketed under overlapping "shockwave" terminology, which created the patient confusion we deal with today.

Softwave technology, which Apex uses, is a more recent unfocused electrohydraulic system. It produces true acoustic shockwaves (not pressure waves) but distributes them broadly rather than concentrating them at a focal depth. The biological mechanism is similar to focused shockwave but the dose distribution is different.

How it actually works

The mechanism people usually hear is "it breaks up scar tissue" or "it stimulates new blood vessels." Both are partially true but miss the more interesting part.

Shockwave produces a brief, high-amplitude acoustic pulse that causes mechanotransduction in tissue. The cells experience a transient mechanical signal, and a set of downstream pathways activate: VEGF (vascular endothelial growth factor) expression goes up, eNOS (endothelial nitric oxide synthase) upregulates, certain immune cells are recruited, BMP-2 (bone morphogenetic protein-2) increases, growth factor signaling around the treated area changes. The result, over the course of a treatment series, is increased local vascularity, improved cellular repair signaling, and (for tendons) increased fibroblast proliferation and collagen synthesis.

This is not a thermal effect (the tissue isn't heated). It's not a mechanical destruction effect at our energy levels (the tissue isn't physically torn). It's a signal. A loud, controlled, repeated mechanical tap that says "wake up and repair."

The effect is more pronounced in tissues where the resident cells still have the capacity to repair but aren't being told to. Tendinopathy is the classic example: a chronically degraded tendon often has the cellular machinery for healing but lacks the signal. Shockwave provides the signal.

There's also evidence that shockwave at clinical doses can stimulate mesenchymal stem cell mobilization from local niches, which is one reason combining it with cellular therapy (either patient-mobilized or exogenously delivered) makes biological sense.

The physics, in plain English

For the curious, a brief tour of what's actually happening:

An electrohydraulic shockwave is generated by triggering a brief electrical discharge underwater. The discharge creates a tiny plasma bubble that expands rapidly and then collapses, generating an acoustic pulse with a steep rise time (nanoseconds), a peak positive pressure in the megapascal range, and a brief trailing tensile component. The pulse is then shaped (focused, defocused, or distributed depending on device) and transmitted through a coupling medium (typically gel) into the patient's tissue.

The acoustic pulse propagates through tissue and produces both compressive and shear forces at cellular and subcellular scales. The cellular response is mechanotransductive: cells convert the mechanical stimulus into biological signaling. The receptors involved include integrins, ion channels, and primary cilia.

The "shockwave" terminology specifically refers to the steep rise time of the pressure pulse. A pressure wave with a slower rise (such as those produced by radial pressure-wave devices) is biologically different even if it feels similar from the patient's side of the treatment.

Focused vs unfocused vs radial: the distinction matters

This is the part of the conversation where patients get confused, often deliberately by clinics that don't want to distinguish.

Focused shockwave concentrates the acoustic energy at a specific depth, like a focused beam. Higher energy density at the focal point. Used for deeper structures and for high-energy applications like calcific tendinitis fragmentation.

Unfocused (planar) electrohydraulic shockwave (Softwave) produces true acoustic shockwaves but distributes them across a wider tissue volume. Lower energy density at any single point, broader treatment area. Well-suited for distributed soft tissue indications.

Radial pressure-wave devices use a compressed-air-driven projectile striking a transmitter. They produce pressure pulses (not true shockwaves) with slower rise times and lower peak pressures. They feel similar from the patient's perspective but are biologically different. Energy decays rapidly with depth, so radial devices treat superficial tissue more than deep structures.

All three are sometimes marketed under "shockwave" terminology. The clinical literature distinguishes them. The patient often doesn't know to.

For most musculoskeletal soft tissue indications, unfocused or focused shockwave (true acoustic shockwave) is the higher-evidence modality. Radial pressure-wave has some evidence for surface indications but produces less robust biological effects.

When evaluating a "shockwave" clinic offering, ask which technology specifically. The answer should be more specific than "shockwave."

What the evidence shows by indication

The strongest evidence is for:

Plantar fasciitis. Multiple RCTs and systematic reviews show shockwave significantly improves heel pain and function in chronic plantar fasciitis, particularly cases that have failed first-line conservative management. The FDA cleared shockwave for plantar fasciitis in 2000 based on this evidence base.

Lateral epicondylitis (tennis elbow). Solid evidence for moderate-to-large improvements, comparable to or better than steroid injections at 6 to 12 months, without the long-term tendon-quality cost steroid creates. The Mani-Babu systematic reviews are reasonable starting points.

Patellar tendinopathy (jumper's knee). Reasonable RCT evidence in athletes and recreational populations. Often combined with eccentric loading programs.

Calcific shoulder tendinopathy. The high-energy variant (focused shockwave at higher dose) has good evidence for breaking up calcium deposits and reducing symptoms. The lower-energy variants have evidence for the symptomatic improvement without necessarily fragmenting the calcium.

Achilles tendinopathy. Solid evidence for non-insertional tendinopathy; mixed for insertional. The mid-portion Achilles tendinopathy is the cleaner indication.

The evidence is weaker, but emerging, for:

Plantar plate injuries (forefoot).

Gluteal tendinopathy and greater trochanteric pain syndrome.

Hamstring tendinopathy and chronic high hamstring strains.

Hip osteoarthritis (mild to moderate). Some emerging studies suggest a symptomatic benefit, though the structural effects are modest.

Frozen shoulder (adhesive capsulitis). Mixed evidence, some positive trials.

The evidence does not currently support shockwave as a primary treatment for moderate-to-severe osteoarthritis. If a clinic is marketing it as a "non-surgical knee replacement," they're outrunning the literature.

The erectile dysfunction application of shockwave (a different protocol, lower energy, different device parameters, applied to penile tissue) has growing evidence and a substantial FDA-cleared device market. We don't currently offer this at Apex.

Treatment parameters

For the technically curious, a typical Softwave session looks like:

• Energy flux density: in the low-to-moderate range, typically 0.1 to 0.3 mJ/mm²
• Number of pulses per session: 1,500 to 3,000 depending on area and indication
• Treatment frequency: every 5 to 10 days
• Course length: 4 to 6 sessions for most indications
• Coupling: standard ultrasound gel
• Pretreatment: no analgesia or local anesthetic needed at our typical energy levels (and ideally avoided because we want the patient feedback to titrate dosing)

The specific parameters get tuned to the indication, the depth of the target tissue, and patient comfort during the session.

How we use shockwave at Apex

Three roles, depending on the case.

As a standalone treatment. For early or mid-stage tendinopathy where the tissue has capacity to remodel but isn't getting the right signal, a course of 4 to 6 sessions is often the right answer. It's cheaper than a stem cell protocol, has its own evidence base, and works in the population the literature actually supports.

As tissue priming before a regenerative injection. For more degraded tissue, we sometimes run a course of shockwave before a PRP or stem cell injection. The biological rationale is straightforward: increasing local vascularity and waking up cellular repair signaling before delivering the cellular or growth-factor payload should improve the response. The clinical evidence for this sequencing is suggestive rather than conclusive, and we tell you when we're using it that way.

As maintenance. Some patients with chronic tendinopathies do well with periodic shockwave maintenance sessions every few months.

What a session looks like

You'll lie on the treatment table. The therapist applies ultrasound gel and runs the shockwave applicator over the treatment area for 8 to 15 minutes. You'll hear and feel a tapping sensation. The energy level is set to be uncomfortable but not painful. No anesthesia required, no needles. You drive yourself home.

The sound is louder than you'd expect from a clinical device. It's the audible component of the acoustic shockwave. We'll offer earplugs or headphones if the noise bothers you.

The sensation varies by treated tissue. Over a sensitive tendon, it can feel like a series of brisk taps that border on uncomfortable; that's the desired dose. Over more tolerant tissue (a thicker muscle belly, for instance), it's barely noticeable. Patient feedback during the session helps us titrate. The right dose is "perceptible and slightly uncomfortable, not painful."

We treat the area for 8 to 15 minutes, varying applicator position to cover the target tissue and surrounding structures.

Post-session, most patients experience:

• Mild local soreness for 24 to 72 hours, similar to the muscle ache after a workout.
• Occasionally light bruising or transient redness over the treated area.
• No restriction on normal activity. You can drive immediately, return to work, and resume most exercise within a day.

Symptom improvement typically lags treatment by a few weeks. People often report continued improvement for 6 to 8 weeks after the final session as the underlying tissue remodeling catches up to the signaling.

When shockwave isn't the right tool

A few situations where we'd recommend against it:

An acute injury, where the tissue is already in active repair and you're better off resting it. Shockwave is for chronic or stalled cases, not fresh trauma.

A complete tendon tear or rupture, which is a surgical question.

Active local infection in the treatment area.

Pregnancy in any area where the device could affect the abdomen or pelvis.

Bleeding disorders or anticoagulation that meaningfully increases bleeding risk.

A pacemaker or implantable cardiac device near the treatment area (rare concern but worth screening).

An indication that just isn't supported by the evidence, like advanced bone-on-bone osteoarthritis with no soft tissue component to wake up.

Combining shockwave with other modalities

For the right cases, shockwave layers well with:

PRP. Shockwave first to prime the tissue, PRP injection 2 to 4 weeks later. Useful in chronic recalcitrant tendinopathy where neither modality alone has worked.

Stem cell or exosome therapy. Same logic, larger biological payload. Shockwave course completed before the cellular procedure.

Eccentric exercise programs. Particularly for Achilles and patellar tendinopathy. Shockwave plus eccentrics is the higher-evidence combination than either alone.

Photobiomodulation (LED and laser). Some patients respond well to combined photonic and acoustic protocols, particularly for surface tendinopathies.

For wrong cases, shockwave doesn't combine usefully with steroid injection (the inflammatory burst shockwave triggers is partly the active ingredient, and steroid blunts it). We avoid the combination.

Home shockwave devices

A few consumer-market devices are now sold under "shockwave" branding. Most fall into one of these categories:

• Low-power radial pressure-wave devices marketed at clinical-sounding language.
• Massage guns marketed misleadingly as "shockwave."
• Genuinely low-quality knockoffs of clinical units, often imported, with no FDA clearance.

None of them deliver clinical-grade energy density. Some are genuinely useful for self-massage and muscle recovery, but they're not biologically equivalent to clinical shockwave therapy. If a friend tells you they bought a home shockwave device that "works just like the clinic," they almost certainly bought something that's adjacent to but materially different from what we use.

How it fits into a protocol

For most patients, shockwave is one of three or four tools we'll consider, and which tool we choose depends on the diagnostic workup. The protocol falls out of the indication. If shockwave is the right answer, we use it. If it's wrong, we don't add it for the sake of having something to add.

In our typical case load:

• About a quarter of new patients leave their initial visit with shockwave as part of the plan, usually as a standalone first step or as part of a sequenced regenerative protocol.
• A smaller percentage receive shockwave maintenance care for chronic tendinopathy that responds well to periodic sessions.
• The majority of patients getting cellular therapy don't receive shockwave priming, because the cellular procedure alone is sufficient for their indication.

If you've been told by another clinic that you need a "stem cell plus shockwave plus laser plus PRP plus IV vitamin therapy" combination protocol, the question to ask is whether each modality is doing distinct work, or whether the bundle is more marketing than medicine. Both are possible. The answer should be evidence-based and case-specific.

The cost question

Shockwave sessions at Apex run $300 to $450 per session. A typical course of 4 to 6 sessions runs $1,200 to $2,400, with some pricing flexibility for committed courses.

Insurance coverage for orthopedic shockwave is inconsistent. Some plans cover it for plantar fasciitis (the original FDA-cleared indication); most don't cover it broadly. We don't bill insurance for shockwave but can provide a superbill for HSA/FSA reimbursement.

Compared to either a single PRP injection or a series of steroid injections, shockwave can be cost-competitive for the indications where the evidence supports it. The math gets more favorable when shockwave is the appropriate standalone treatment vs an unnecessary cellular procedure.

How to know if you're a candidate

The short list of indications where shockwave is most likely the right tool:

• Plantar fasciitis that has failed 6+ weeks of conservative care (rest, ice, stretching, orthotics).
• Lateral epicondylitis at 3+ months of symptoms.
• Patellar tendinopathy in active or formerly active patients.
• Chronic mid-portion Achilles tendinopathy.
• Calcific shoulder tendinopathy with imaging-confirmed deposits.
• Greater trochanteric pain syndrome that has failed PT and conservative care.

If your clinical picture matches one of these and you've already done a fair trial of conservative measures, shockwave is worth considering before escalating to injection-based therapies.

How to book

To talk through whether shockwave is the right tool for your case, request a consultation or call (972) 768-2328.

A short note from Dr. Abdullah

Shockwave is one of the most underused, evidence-supported tools in regenerative medicine. It's not glamorous, the marketing departments at most clinics don't get excited about it, and it can't be priced anywhere near a cellular protocol. But for the right indication, it works, the evidence is solid, and the patient gets a real result for substantially less money than the more aggressive options. That's a combination worth taking seriously, especially for patients who arrive convinced they need the most expensive option available. Sometimes the right answer is the inexpensive one.